Претраживање
Приказ резултата 1-10 од 18
Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site / Doking studije nekih jedinjenja sa pirazolom u aktivnom mestu ciklooksigenaze-2
(Savez farmaceutskih udruženja Srbije (SFUS), 2023)
Whereas nonselective nonsteroidal anti-inflammatory drugs, such as aspirin, ibuprofen and
diclofenac, inhibit both cyclooxygenase-1 and cyclooxigenase-2 enzymes, selective inhibitors
target cyclooxygenase-2, which is ...
Neuropharmacokinetics: the secret life of - old and novel - psychopharmacological drugs
(International Association of Physical Chemists, 2023)
Neuro pharmacokinetics: the secret life of - old and novel - psychopharmacological drugs
Miroslav Savić
Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Serbia
In the 21st century, the pace of ...
Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application
(International Association of Physical Chemists, 2023)
Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application
Jelena Đoković1, Bojan Marković2, Dishary Sharmin3, James M Cook3, Miroslav ...
Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73
(Macedonian Pharmaceutical AssociationSs. Cyril and Methodius University in Skopje, Faculty of Pharmacy, 2023)
Nanopharmaceuticals offer a good option to avoid
some of the difficulties that novel drug candidates
confront. They can be tailored to adjust their water
solubility, half-life, biodistribution, and govern the release
of ...
Selected thiourea derivatives of naproxen as potential anti-inflammatory agents: in vivo, in vitro, and in silico approach
(Fakultet medicinskih nauka Univerziteta u Kragujevcu, 2023)
The aim of the conducted study was to develop new potential dual COX-2 and 5-LOX
inhibitors based on naproxen scaffold. We performed the evaluation of in vivo and in vitro
anti-inflammatory activity of newly synthesized ...
Sizing experiments and bio-nano interactions: method matters
(4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France, 2023)
INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as ...
Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer
(4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France, 2023)
INTRODUCTION
Nanoemulsions (NEs) offer a flexible platform for drug delivery via several administration routes. Rapid plasma clearance brought on by interactions with plasma proteins and the activation of the mononuclear ...
Biocompatible nanoemulsions as a tool for preclinical testing of CW-02-79, a pyrazoloquinolinone modulator of sigma-2 receptors: preformulation and formulation studies
(4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France, 2023)
INTRODUCTION
Recently, the modulation of sigma-2 receptors localized in the brain is proposed to be linked with regulation of mood, anxiety, and cognition [1]. Hence, we hypothesized that novel patent-protected ligand of ...
Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): Process parameters and lyoprotectant selection through the stability study
(Elsevier B.V., 2023)
Recently, nanocrystal dispersions have been considered as a promising formulation strategy to improve the bioavailability of the deuterated pyrazoloquinolinone ligand DK-I-56-1 (7‑methoxy-2-(4‑methoxy-d3-phenyl)-2,5-dihy ...
Discovery of Novel Thiophene/Hydrazones: In Vitro and In Silico Studies against Pancreatic Cancer
(MDPI, 2023)
Cancer is the disease with the highest mortality. Drug studies contribute to promising treatments; however there is an urgent need for selective drug candidates. Pancreatic cancer is difficult to treat and the cancer ...